|
A.A. Gavrilova, R.A. Bontsevich
Analysis and optimization of approaches to the treatment of community-acquired pneumonia in real clinical practice
|
№5 / 2022
|
|
S.V. Zaitseva, O.V. Zaitseva, E.E. Lokshina
Actual issues of etiology, diagnosis and therapy of community-acquired pneumonia in children
|
№1 / 2020
|
|
R.I. Shaymuratov, A.A. Vizel
Risk factors for fatal outcome in patients with community-acquired pneumonia
|
№5 / 2019
|
|
A.I. Sinopalnikov
Antibiotics and community-acquired low respiratory tract infections. Who for? What preparation?
|
№5 / 2019
|
|
A.A. Zaitsev (1), A.V. Vlasova (2)
COMPLIANCE WITH ANTIBIOTIC THERAPY FOR RESPIRATORY TRACT INFECTIONS
|
№20 / 2016
|
|
I.A. Dronov (1,2), M.D. Shakhnazarova (2)
THE ROLE OF MACROLIDES IN THE TREATMENT OF ACUTE BRONCHITIS AND COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN
|
№1 / 2016
|
|
A.A. Vizel, G.V. Lysenko
FEATURES OF THE MANAGEMENT OF PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA IN TATARSTAN
|
№15 / 2014
|
|
A.I.Sinopalnikov
COMMUNITY-ACQUIRED PNEUMONIA "NOT RESPONDING" TO ANTIBACTERIAL THERAPY
|
№15 / 2014
|
|
A.I. Sinopalnikov (1), R.S. Kozlov (2), S.A. Rachina (2, 3), N.N. Dekhnich (4)
CURRENT RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA
|
№3 / 2014
|
|
A.S. Belevsky
CURRENT POTENTIALS FOR ADJUVANT THERAPY OF COMMUNITY-ACQUIRED PNEUMONIA
|
№6 / 2013
|
|
I.V. Leshchenko1,2, Z.D. Bobyleva1, A.V. Krivonogov2
Macrolides In Severe Pneumonia: Why And How To Appoint?
|
№15 / 2012
|
|
V.E. Nonikov, S.A. Evdokimova, E.V. Ponomareva
Diagnosis And Algorithm Of Treatment Of Community-acquired Pneumonia
|
№15 / 2012
|
Русский
